I am searching for prognostic and therapeutic biomarkers for Kaposi Sarcoma Herpesvirus (KSHV)-induced oncogenesis by analyzing the humoral and T-cell responses to KSHV infection, with the ultimate goal of developing vaccines and other immune therapies to treat or prevent Kaposi Sarcoma.

I am working to foster engagement across the local biotech community through various initiatives, including but not limited to crafting strategic newsletters that unify and inspire students, entrepreneurs, and industry leaders, aiming to grow and strengthen the biotech ecosystem in the Greater New Orleans area.

I worked on several projects aimed to create or improve innovative allogeneic, iPSC-derived T-cell therapies. The overall goal of these projects is to provide more effective, tolerable, and accessible treatments for patients diagnosed with B-cell malignancies or solid tumors.

I worked under Adam Bohnert, Ph.D. to discover the genetic origins of newly discovered tubular lysosomes using C. elegans as a model organism. The primary focus of this project is to determine how these structures affect, or are affected by, the process of aging.

Thesis work was done under the direction of Artem Barski, Ph.D. where I worked with cutting-edge technologies to understand the epigenetic principles of rapid recall ability of memory T cells as well as pursuing ways to use CRISPR technology to epigenetically alter the Th2 response in the context of atopic disease.